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The biological roles of cyclic nucleotide phosphodi-
esterase 11 (PDE11) enzymes are poorly understood,
in part due to the lack of selective inhibitors.
To address the need for such compounds, we
completed an 200,000 compound high-throughput
screen (HTS) for PDE11 inhibitors using a yeast-
based growth assay, and identified 4 potent and
selective PDE11 inhibitors. One compound, along
with two structural analogs, elevates cAMP and
cortisol levels in human adrenocortical cells, consis-
tent with gene association studies that link PDE11
activity to adrenal function. As such, these com-
pounds can immediately serve as chemical tools to
study PDE11 function in cell culture, and as leads to
develop therapeutics for the treatment of adrenal
insufficiencies. Our results further validate this
yeast-basedHTSplatform for thediscoveryofpotent,
selective, and biologically active PDE inhibitors.
INTRODUCTION
The second messengers cyclic AMP (cAMP) and cyclic
GMP (cGMP) regulate a myriad of processes such as cell prolif-
eration, differentiation, apoptosis, inflammation, hormone secre-
tion, muscle contraction, and cognitive functions (Bender and
Beavo, 2006; Conti and Beavo, 2007). Intracellular cAMP and
cGMP levels are determined by the balance between their
synthesis by adenylate or guanylate cyclases and their degra-
dation by phosphodiesterases (PDEs). In mammals, 21 genes
encode 100 PDE isoforms that are grouped into 11 families
based on their substrate specificity, overall sequence conserva-
tion, and regulatory properties. The unique tissue expression
and subcellular localization patterns of PDE enzymes, together
with their diversity and differences in enzymatic properties, allow
individual isoforms to control specific physiological functions
and link them to different pathological conditions. Therefore,
selective PDE inhibitors have the potential to provide therapeutic
benefit to a wide range of diseases (Bender and Beavo, 2006;
Conti and Beavo, 2007).
PDE11 is the most recently discovered PDE family (Fawcett
et al., 2000). In humans the PDE11A gene encodes four isoformsChemistry & Biology 19, 155that are dual-specificity enzymes, hydrolyzing both cAMP and
cGMP (Fawcett et al., 2000; Hetman et al., 2000; Yuasa et al.,
2000). PDE11A is expressed in skeletal muscle, prostate, testis,
brain, kidney, liver, pancreas, lymphoid cells, and pituitary and
adrenal glands (D’Andrea et al., 2005; Dong et al., 2010; Lakics
et al., 2010; Loughney et al., 2005; Seftel, 2005), but the biolog-
ical roles of PDE11 in these tissues are poorly understood due to
the lack of selective inhibitors. PDE11A knockout mice display
subtle alterations in sperm function (Wayman et al., 2005) and
psychiatric disease-related phenotypes (Kelly et al., 2010). The
absence of more dramatic phenotypes may be due to compen-
sation by other PDEs during development that masks normal
roles for PDE11.
Genetic defects of PDE11A have been linked to major depres-
sion, bipolar disorder, asthma, adrenal, testicular, and prostatic
cancers in genome-wide association studies (DeWan et al.,
2010; Fatemi et al., 2010; Faucz et al., 2011; Horvath et al.,
2009; Libe´ et al., 2011; Wong et al., 2006). In addition, inactivat-
ingmutations of PDE11A are found in patients with several forms
of adrenal hyperplasia and Cushing syndrome, which results
from excess cortisol release from adrenocortical tumors (Boikos
et al., 2008; Carney et al., 2010; Horvath et al., 2006a, 2006b;
Libe´ et al., 2011). Adrenal tumor homogenates from these
patients have elevated cyclic nucleotide levels and increased
CREB phosphorylation, suggesting that PDE11 plays a major
role in controlling cAMP and cGMP levels in these tissues (Hor-
vath et al., 2006a). In addition the PDE5 inhibitor tadalafil, cur-
rently used to treat erectile dysfunction, has significant activity
against PDE11 (Weeks et al., 2005). Thus, PDE11-specific inhib-
itors would be useful for studying the biological roles of PDE11
and in clarifying any PDE11-related side effects of this commonly
prescribed drug.
We previously reported the development of a fission yeast
cell-based screening platform to identify small molecule in-
hibitors of mammalian PDEs (Alaamery et al., 2010; Demirbas
et al., 2011a, 2011b; Ivey et al., 2008). The screen employs
genetically engineered yeast strains whose growth behavior
reflects the activity of heterologously expressed PDEs. The cells
express a ura4 reporter that is regulated by PDE activity and is
counterselectable for growth in medium containing 5-fluoroor-
otic acid (5FOA). Cells lacking both adenylate cyclase and PDE
activity respond to low levels of exogenous cAMP or cGMP to
activate PKA and, thus, repress ura4 expression, conferring
5FOA resistance (5FOAR). Cells that express PDEs that hydro-
lyze the exogenously added cGMP (or cAMP) remain 5FOA–163, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 155
Figure 1. Optimization of Growth Assay to
Identify PDE11 Inhibitors
(A) Screening strains possess the fbp1-ura4
reporter, whose expression can be repressed by
PKA, which is activated by the addition of cGMP to
the growth medium. PDE11 hydrolysis of cGMP
allows ura4 expression, producing a 5FOAS
phenotype (top panel). PDE11 inhibition elevates
intracellular cGMP levels to confer 5FOAR growth
(bottom panel).
(B) 5FOA growth assays with strains lacking PDE
activity (cgs2-2 is a frameshift allele of the only
S. pombe PDE gene; Wang et al., 2005b) or ex-
pressing human PDE11A4 were performed in
0–2 mM cGMP.
(C) 5FOA growth assays with a strain expressing human PDE11A4 inmedium containing either 0.2%DMSO or 25 mMBC76, with varying concentrations of cGMP
(0–0.2 mM). The vertical line indicates the cGMP concentration that produces the maximum difference in average OD between the DMSO-treated and BC76-
treated cultures. Values are the mean of three experiments (with three wells per condition in each experiment) ± SEM.
See also Figure S1.
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a PDE inhibitor confers 5FOAR growth (Figure 1A, bottom panel).
Using strains that express 10 of the 11 PDE families, this yeast-
based assay allows us to identify and profile PDE inhibitors. We
have used this platform to identify PDE4 and PDE7 inhibitors that
are biologically active in mammalian cells (Alaamery et al., 2010).
In this study we present the use of this screening platform to
develop and perform a high-throughput screen (HTS) for
PDE11 inhibitors. We identified four highly selective and potent
compounds, as judged by in vitro enzyme assays and yeast-
based growth assays. To our knowledge, these are the first
PDE11-selective inhibitors to be reported. We further use these
compounds to demonstrate a biological role of PDE11 in cortisol
production in H295R adrenocortical carcinoma cells. One of
these compounds, BC11-38, increases cAMP levels, PKA-medi-
ated ATF-1 phosphorylation, and cortisol production in these
cells. By comparing the effects of BC11-38 and structural
analogs on H295R cells versus HeLa cells, which have little or
no PDE11A expression, we demonstrate that the biological
effects of these compounds are due to PDE11 inhibition.
RESULTS
Optimization and Performance of a Yeast-Based HTS
for PDE11 Inhibitors
We used a fission yeast-based assay to develop and conduct
a HTS for PDE11 inhibitors. The screening strain was generated
by replacing the open reading frame of the only S. pombe PDE
gene, cgs2+, with a human PDE11A4 cDNA, via homologous
recombination (Demirbas et al., 2011b). Compared with cells
that lack PDE activity, cells expressing PDE11A4 require more
cyclic nucleotide in the growth medium to achieve 5FOAR (Fig-
ure 1B; Figure S1 available online), indicating that the expressed
enzyme is functionally active in yeast. Because expression of
PDE11A4 creates a greater increase in the amount of exogenous
cGMP (Figure 1B) than cAMP (Figure S1) required to promote
growth, HTSs for PDE11A4 inhibitors were carried out in the
presence of cGMP.
We next optimized the growth and assay conditions for the
detection of PDE11 inhibitors, using a previously identified
nonselective PDE inhibitor, BC76 (Demirbas et al., 2011b), as156 Chemistry & Biology 19, 155–163, January 27, 2012 ª2012 Elseva positive control. The optimal preassay growth conditions, initial
cell density, and cGMP concentration in the screening medium
that confer saturated growth only in the presence of BC76
were determined. A total of 60 mM cGMP allows cells to grow
to saturation (optical density [OD] 1.1) after 48 hr at 30C in
the presence of 25 mM BC76 but fails to promote growth of
PDE11-expressing cells in the absence of BC76 (OD 0.2;
Figure 1C).
In the HTS, PDE11-expressing cells were grown in 5FOA
medium for 48 hr in the presence of 20 mM test compounds,
and growth in each well was assessed by measuring OD.
Robustness of the screening conditions was determined by
a Z0 factor analysis. The optimized screening conditions pro-
duced Z0 factors of 0.7–0.9, indicative of a robust screen. A total
of 198,382 compoundswere screened in duplicate in the primary
screen. The Z scores of the duplicate wells are shown in Fig-
ure 2A. Candidate ‘‘hit’’ compounds were defined based on their
composite Z scores, which reflect both the level of growth stim-
ulation and the reproducibility of the replicate assays (Figure 2B).
The composite Z scores for BC76 positive control wells ranged
from 26 to 148. Test compounds that promoted significant
5FOAR growth were grouped by their composite Z scores as
strong (>35), moderate (26–35), or weak (20–26) hits (Figure S2).
Selection of PDE11-Specific Inhibitors
The process by which we analyzed 198,382 compounds to iden-
tify 4 PDE11-specific inhibitors is presented in Figure 3. Data
from our previous screens for inhibitors of PDE8 (D. Demirbas
and C.S.H., unpublished data), PDE4, and PDE7 (Alaamery
et al., 2010) were used to identify nonselective PDE inhibitors
and compounds that stimulate cell growth via PDE-independent
mechanisms from among the 1,143 hit compounds in this screen
(Figure 3). For confirmation of hits and to further eliminate
nonspecific inhibitors, the top 595 hits based on composite Z
scores (0.3% of the total number of compounds screened)
were subjected to a confirmatory screen using the PDE11-
expressing strain, and 2 counterscreens using PDE5- and
PDE10-expressing strains (PDE5 and PDE10 are the 2 PDEs
most structurally similar to PDE11). Although data from previous
screens allowed us to exclude many nonselective and off-target
hits, a small group of these primary hit compounds was found toier Ltd All rights reserved
Figure 2. HTS Data Summary
(A) Scatterplot represents Z scores for duplicate
wells pinned with 0.2% DMSO (negative controls;
gray circles), 25 mMBC76 (positive controls; white
circles), or screening compounds (black circles).
(B) Composite Z score distribution of the screened
compounds. The height of each bar represents the
number of screened compounds displaying the
corresponding composite Z score in the x axis.
The x axis is binned into 537 bins with intervals of
0.4. Compounds with composite Z scores >20 are
defined as hits.
See also Figure S2.
Figure 3. Overview of the Processing of Initial Hit Compounds
Of 198,382 compounds screened, 1,143 hits were considered for further
characterization. Compounds that were also detected as hits in our previous
PDE8, PDE4, and PDE7 screens were excluded, as indicated in the pie chart.
Of the remaining 798 compounds, the most effective 595 candidates (cherry-
picks; as determined by composite Z score) were rescreened using the
PDE11-expressing strain and counterscreened using PDE5- and PDE10-
expressing strains. A total of 99 compounds conferred 5FOAR growth in the
rescreen using the PDE11-expressing strain, but not in the counterscreens.
The most selective and potent 39 compounds were acquired and tested in
secondary assays (a full panel of in vitro enzyme assays and 5FOA growth
assays), leading to the identification of 4 PDE11-specific inhibitors. See also
Figure S3.
Chemistry & Biology
Biologically Active PDE11-Selective Inhibitorsinhibit PDE5 and PDE10 in the counterscreens (Figure S3). From
the 99 compounds that promoted growth of the PDE11-express-
ing strain but not the PDE5- or PDE10-expressing strains, 39
lead candidates were selected for secondary assays, based on
their potency and selectivity. In addition only the most effective
one or two members of a set of compounds that share a large
substructure were studied.
The 39 lead compounds were characterized by 5FOA growth
assays using yeast strains that express PDEs representing 10
of the 11 mammalian PDE families (with the exception of
PDE6) and in a PDE11 in vitro enzyme assay. Compounds that
promoted growth of only the PDE11-expressing strain in the
yeast growth assays and had IC50 values <2 mM against
PDE11 were further tested using in vitro enzyme assays against
PDEs representing the other 10 PDE families (PDE1–PDE10). In
this manner we identified four highly selective and potent
PDE11 inhibitors. In 5FOA growth assays these compounds
stimulate growth of the PDE11-expressing strain at <10 mM,
whereas having little to no effect on any of the strains expressing
other PDEs at %100 mM (Figure 4A; data from exposure to
>30 mM compound are not shown to avoid compression of
data at low compound concentrations). They display IC50 values
%330 nM for PDE11 and >100-fold selectivity for PDE11 relative
to other PDEs as judged by in vitro enzyme assays, with the
exception of BC11-19 that is only 30-fold selective for PDE11
relative to PDE1 (Figure 4B). To our knowledge, these com-
pounds are the first identified PDE11-selective inhibitors.
PDE11-Selective Inhibitors Elevate cAMP Levels and
Cortisol Production in Adrenocortical Cells
PDE11 is expressed in adrenal glands, and PDE11-inactivating
mutations, as well as elevated cAMP levels, have been identified
in patients with adrenocortical tumors and Cushing syndrome,
a condition resulting from excess cortisol release from adrenal
tumors (Boikos et al., 2008; Carney et al., 2010; Horvath et al.,
2006a, 2006b). To test whether phenotypes associated with
PDE11 inactivation in Cushing syndrome (i.e., elevated cAMP
and cortisol levels) could be mimicked by treatment of adreno-
cortical cells with our PDE11-specific inhibitors, we examined
the effect of these compounds on H295R human adenocarci-
noma cells (Rainey et al., 1994). We found that BC11-38 signifi-
cantly increased cAMP levels and cortisol production in H295R
cells, both in the absence and presence of the adenylate cyclase
activator forskolin (Figure 5). As a control, the nonselective PDE
inhibitor IBMX (500 mM) was used to eliminate all PDE activity,
with the exception of PDE8 and PDE9, in order to assess theChemistry & Biology 19, 155relative importance of PDE11 on cAMP hydrolysis in these cells.
These data suggest that PDE11 represents a significant propor-
tion of the cAMP PDE activity and has a major role in regulating
cortisol production in H295R cells. Because the IC50 values for
IBMX against various PDEs range from 2 to 50 mM (Bender and
Beavo, 2006; Conti and Beavo, 2007), we used 500 mM IBMX
to measure the effect of near-complete inhibition of all PDEs
with the exception of PDE8 and PDE9. However, at this concen-
tration, off-target effects of IBMX treatment may have prevented–163, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 157
Figure 4. Four Potent and Selective PDE11
Inhibitors Identified by the HTS
(A) Profiling of PDE11-specific inhibitors in yeast
growth assays. Four PDE11-selective inhibitors
were profiled using strains expressing 10 of the 11
PDE families. Dose-response growth curves in the
presence of %30 mM compound from one repre-
sentative (with duplicate wells for each data point)
of triplicate experiments are presented.
(B) Structures and IC50 values of PDE11-specific
inhibitors in in vitro enzyme assays. Because the
assays were carried out at substrate concentra-
tions of one-tenth the KM of the enzymes, the IC50
values approximate the Ki values for these com-
pounds. MW, molecular weight.
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used at 20 mM, the maximal effective concentration in these
assays. The failure to elevate cAMP and cortisol levels by
BC11-15, BC11-19, and BC11-28 suggests that these com-
pounds either fail to enter the cells due to poor solubility in tissue
culture media or have a detrimental effect on cells. Consistent
with this idea, compounds BC11-15 and BC11-28 have high
LogP values (>4.7), suggesting that they may be too lipophilic
for these assays. Alternatively, the effect of BC11-38 may be
due to an off-target activity.
Biological Effects of BC11-38 and Related Compounds
Are Due to PDE11 Inhibition
To address the possibility that BC11-38 elevates cAMP levels
and cortisol release by H295R cells in a PDE11-independent
manner, we analyzed four structural derivatives of BC11-38
that differ by a single methyl or methoxy group. The potency of
these compounds against PDE11 (Figure 6A) is consonant with
their ability (at 20 mM) to elevate cAMP levels and cortisol
production (Figure 6C) in H295R cells. Transcription of genes158 Chemistry & Biology 19, 155–163, January 27, 2012 ª2012 Elsevier Ltd All rights reserveencoding several key enzymes involved
in cortisol production by adrenocortical
cells is activated by the cAMP-response
element (CRE)-binding proteins (Almeida
and Stratakis, 2011; Stratakis, 2009).
Because ATF-1 and CREM are the major
proteins that bind the CRE in H295R cells,
which lack CREB, and are phosphory-
lated by PKA in response to elevated
cAMP levels to activate transcription,
we analyzed the phosphorylation state
of ATF-1 in H295R cells (Groussin et al.,
2000; Rosenberg et al., 2002; Wang
et al., 2000). BC11-38 and its derivatives
elevate ATF-1 phosphorylation in a man-
ner that corresponds with their potency
against PDE11 (Figure 6B).
To further test whether the biological
activity of BC11-38 and related com-
pounds is due to PDE11 inhibition, we
examined PDE11A transcription in a
group of cell lines, finding very low levels
of PDE11A mRNA in several lines in-cluding HeLa and MDA-MB-231 cells (Figure 6D). Consistent
with PDE11 inhibition as the primary effect of these compounds,
neither BC11-38 nor its derivatives affect cAMP levels or CREB
phosphorylation in HeLa cells (Figure 6E). Similarly, BC11-38
fails to elevate cAMP levels and CREB phosphorylation in
MDA-MB-231 cells (Figure S4). These results suggest that the
biological effects of BC11-38 and related compounds in adreno-
cortical cells are due to PDE11 inhibition.
DISCUSSION
Increasingly, yeast-based HTSs are being used to discover
compounds for the study and treatment of human disorders
(Couplan et al., 2011; Marjanovic et al., 2010). Here, we demon-
strate the use of a fission yeast-based screen to identify potent
and selective human PDE11 inhibitors. One inhibitor discovered
in our screens, BC11-38, along with two derivatives, elevates
cAMP levels and cortisol production in adrenocortical cells in
a PDE11-specific manner, mimicking the phenotypes observed
in Cushing syndrome. Our results demonstrate that thesed
Figure 5. PDE11-Selective Inhibitors Elevate cAMP Levels and
Cortisol Production in H295R Adrenocortical Cells
(A) cAMP levels of H295R cells following a 2 hr treatment with PDE11-specific
inhibitors (20 mM) in the absence or presence of 10 mM forskolin. The nonse-
lective PDE inhibitor IBMX was used at 500 mM as a positive control.
(B) Cortisol release by H295R cells following a 24 hr treatment with PDE11-
specific inhibitors (20 mM) or IBMX (500 mM) in the presence of 10 mM forskolin.
Data are presented as percentage (%) of forskolin plus DMSO-treated cells.
Values represent the averages of at least two independent experiments for
each assay performed in duplicate ± SEM (*p < 0.05, **p < 0.01; as determine
by one-way ANOVA).
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study the biological roles of PDE11 in mammalian cells.
This screening platform has several features that aid in the
identification of biologically active PDE inhibitors. First, the target
PDEs are full-length proteins expressed in eukaryotic cells,
requiring inhibition to occur in the protein-dense yeast cytosol,
which resembles the human cytoplasmic environment. Second,
compounds are detected by their ability to stimulate cell growth,
so that the identified compoundsmust be cell permeable, chem-
ically stable during the 48 hr growth period, and nontoxic to
S. pombe. This last feature is a proxy for high specificity because
compounds that promiscuously bind proteins would likely retard
or inhibit growth. Other favorable features of this screen include
the ability to detect both active site and allosteric inhibitors and
the use of a simple readout to rapidly screen large compoundChemistry & Biology 19, 155libraries. This 384-well format assay allowed us to screen
200,000 compounds, which is larger than any previously pub-
lished yeast-based HTS, to our knowledge. Our ability to identify
potent PDE inhibitors that are biologically active in mammalian
cells in this and other HTSs confirms that S. pombe is well suited
for chemical screening. Using strains that express 10 of the 11
PDE families, we were able to profile inhibitor specificity and
eliminate the majority of nonselective compounds prior to per-
forming in vitro enzyme assays. Similarly, future PDE inhibitor
screens will benefit from the database developed from this and
previous screens to filter out nonselective PDE inhibitors and
compounds that act in a PDE-independent manner.
Although the overall frequency of strong and moderate hits in
this screenwas 0.36%, this frequency varied significantly among
the compound libraries (Figure S2A). Of the large libraries
screened, the highest frequencies of hits were observed in the
Actimol TimTec 1 (0.8%; 68 hits from 8,518 compounds), Chem-
bridge 3 (0.7%; 74 hits from 10,560 compounds), and ChemDiv 6
(0.64%; 283 from 44,000 compounds) libraries. In contrast the
lowest frequency of hits was observed in the ChemDiv 1 library
(0.04%; 6 hits from 16,544 compounds), which may reflect the
fact that this was one of the oldest libraries screened, and
repeated freezing and thawing during previous screens may
have adversely affected these compounds. Interestingly, the
four compounds presented in Figure 4 came from four different
libraries produced by four different companies (BC11-15,
Enamine T0515-1965; BC11-19, Maybridge BTB 12009; BC11-
28, ChemDiv K405-0344; BC11-38, Life Chemicals F0579-
0060).
One unexpected result was that many of the compounds iden-
tified in the initial screen were not validated as PDE11 hits in
cherry-picking experiments. This is likely due to the different
delivery method because the cherry-pick screens use pocket
tips rather than the steel pin arrays used in the primary screens.
It appears that the pocket tip method of introducing compounds
to microtiter dishes fails to allow some compounds to dissolve
in the growth medium. Thus, selection of only validated hits for
secondary assays may have excluded compounds with poor
solubility in growth medium.
PDE11A-inactivating mutations were suggested as predis-
posing factors in the development of adrenocortical hyperplasia
(Horvath et al., 2006a). In these tumors, elevated cAMP levels
and increased CREB phosphorylation result in excess cortisol
release, leading to Cushing syndrome. Here, we confirm the
role of PDE11 in cortisol production by adrenocortical cells,
using selective inhibitors. We observe the disease phenotypes
linked to inactivating mutations in the PDE11A gene using phar-
macological inhibitors of the enzyme in adrenocortical cells, thus
phenocopying a genetic disorder using small molecules. This
directly demonstrates a link between the loss of PDE11 function
with phenotypes related to adrenal hyperplasia and Cushing
syndrome.
Among the four initial PDE11-specific inhibitors, one com-
pound, BC11-38, along with two derivatives, significantly ele-
vates cAMP and cortisol levels in H295R cells. The lack of this
effect by the other compounds does not argue against the
PDE11-specific effect of BC11-38 because it is most likely
related to problems with entry of the compounds into mamma-
lian cells, either due to poor solubility or being bound up by–163, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 159
Figure 6. Biological Activities of BC11-38
and Derivatives Correspond with Their
Potency for PDE11 Inhibition
(A) Structures and IC50 values of BC11-38 deriv-
atives in in vitro enzyme assays. MW, molecular
weight.
(B) cAMP levels (left) and ATF-1 phosphorylation
(right) in H295R adrenocortical cells following
a 2 hr treatment with BC11-38 and derivatives
(20 mM) in the presence of 10 mM forskolin. Cells
were lysed, and proteins were subjected to
immunoblotting with a p-CREB/ATF-1 antibody.
(C) Cortisol release by H295R cells following a
24 hr treatment with BC11-38 and derivatives
(20 mM) or IBMX (500 mM) in the presence of 10 mM
forskolin. Data are presented as percentage (%) of
forskolin plus DMSO-treated cells.
(D) Semiquantitative RT-PCR for PDE11A mRNA
in various cell lines. PDE11A expression was nor-
malized to the expression level of the RPLP0
reference gene.
(E) BC11-38 and related compounds do not
increase cAMP levels or CREB phosphorylation in
HeLa cells. Compound treatment, cAMP assays,
and immunoblots were performed as described
for H295R cells. Values represent the averages of
three separate experiments for each assay per-
formed in duplicate ± SEM (*p < 0.05, **p < 0.01;
determined by one-way ANOVA).
See also Figure S4.
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in the yeast-based assays are more acidic (pH 5.0) than tissue
culturemedia (pH7.0),whichmight contribute to thedifferences160 Chemistry & Biology 19, 155–163, January 27, 2012 ª2012 Elsevier Ltd All rights reservein thesolubility of thecompounds inyeast-
based versusmammalian assays. Indeed,
compound crystals were observed in the
cell culture media in wells containing the
three ineffective compounds, indicating
solubility problems. Due to their biological
activity as well as their biochemical
potency and specificity, BC11-38 and
BC11-38-1 represent a logical starting
point for medicinal chemistry approaches
to enhancepotency, specificity, andphar-
macokinetic properties, to develop com-
pounds suitable for whole-animal studies
of PDE11 function. Such compounds
could produce an acute loss of PDE11
activity as a way of identifying biological
roles for PDE11, which might be over-
looked in knockout mouse studies due to
compensation of activity by other PDEs
or developmental alterations caused by
an early loss of PDE11 activity. These
compounds could also serve as thera-
peutic candidates to treat adrenal insuffi-
ciencies that lead to cortisol deficiency,
such as Addison’s disease. This study
serves as a ‘‘proof of principle’’ that the
yeast-based platform described here
can be used in chemical screens to identify potent and selective
PDE inhibitors that may be effective in cell culture studies even
prior to medicinal chemistry efforts. Such specific compoundsd
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and to develop therapeutics for several diseases related to cyclic
nucleotide signaling defects.
SIGNIFICANCE
The functional importance of PDE11 has been suggested via
gene association studies that link it to a variety of cancers,
psychiatric diseases, asthma, and Cushing syndrome.
However, studies to examine its biological role in different
tissues and these disease states have been hampered
by the lack of selective pharmacological reagents. To our
knowledge, we report the identification of the first selective
PDE11 inhibitors through the use a yeast cell-based HTS of
200,000 compounds. Compounds BC11-38, BC11-38-1,
and BC11-38-2 are commercially available reagents that
we have shown to be suitable for mammalian cell culture
studies to evaluate PDE11 function. These compounds
increase cAMP levels and cortisol production in human
adrenocortical cells, mimicking the phenotypes associated
with Cushing syndrome. Our results demonstrate a direct
role of PDE11 in regulating cortisol production by adrenal
cells, consistent with the presence of missense mutations
in the PDE11A alleles of patients suffering from Cushing
syndrome. These compounds can serve as research tools
even prior to further medicinal chemistry approaches and
as leads for the development of therapeutics for the treat-
ment of adrenal insufficiencies. This study also highlights
the use of the fission yeast Schizosaccharomyces pombe
as a host for the screening of large small molecule libraries
to discover potent, selective, and biologically active PDE
inhibitors. Our ability to use a positive growth selection in
a 384 well format suggests that other HTSs based on the
repression of gene expression could be carried out in
S. pombe using a similar approach.
EXPERIMENTAL PROCEDURES
Yeast Strains, Media, and Growth Conditions
Constructions of S. pombe strains that express mammalian PDEs were previ-
ously described (Demirbas et al., 2011b). Yeast cells were grown and main-
tained using YEA-rich and EMM-defined media as described by Demirbas
et al. (2011b).
5FOA Growth Assays, HTS, and Statistical Analysis
5FOA growth assays were performed using strains that express human
PDE1B1, PDE3A1, PDE4A1, PDE7A1, PDE9A5, PDE10A1, and PDE11A4,
murine PDE2A2 and PDE8A1, and bovine PDE5A1, as described (Demirbas
et al., 2011b).
HTS was performed at the ICCB-Longwood Screening Facility of Harvard
Medical School. Yeast cells that express human PDE11A4 were grown in
EMM medium with 0.25 mM cAMP for 24 hr to 107 cells/ml. The screening
5FOA medium is SC based and contains 0.4 g/l 5FOA. A total of 25 ml
5FOA medium was transferred into duplicate 384-well flat, clear-bottom
microtiter dishes, and 100 nl of compounds (from stock solutions of generally
10–15 mM) was pinned into the wells. Cells were collected by centrifugation,
resuspended in 5FOA medium with 120 mM cGMP, and 25 ml was transferred
into eachwell at an initial cell density of 0.753 105 cells/ml. Control plates con-
sisted of positive control cultures containing 25 and 40 mMBC76 and negative
control cultures containing 0.2% DMSO. Each screening plate included
internal positive and negative control wells. Plates were incubated at 30C
for 48 hr in a closed container with moist paper towels to prevent evaporation.Chemistry & Biology 19, 155ODs of the cultures were measured at 600 nm. In cherry-picking experi-
ments, 100 nl compounds were added using pocket tips instead of steel pin
arrays.
Z0 factors of assays were determined as described (Ivey et al., 2008). An
assay with a Z0 factor >0.5 is considered sufficiently robust for HTS. Within
a screen, individual wells are assigned a Z score, representing the number
of SDs above or below the mean of the negative control wells. Duplicate Z
scores for each compound are plotted onto a grid and projected perpendicu-
larly to the diagonal. A composite Z score is the distance from this point on the
diagonal to the origin.
In Vitro Enzyme Assays
In vitro enzyme assays were conducted via the Ba(OH)2 precipitation method of
Wang et al. (2005a) using recombinant human PDE1C, PDE3B, PDE5A1,
PDE6C, PDE8A, PDE9A2, PDE10A1, PDE11A4, rat PDE2A (BPS Bioscience),
human PDE7A (BIOMOL International), and human PDE4A10 enzymes
(gift from Dr. Hengming Ke). Substrate concentrations used were 100 nM
cGMP (PDE1C), 1 mM cGMP (PDE2A), 30 nM cGMP (PDE3B), 625 nM cAMP
(PDE4A), 500 nM cGMP (PDE5A), 1.7 mM cGMP (PDE6C), 15 nM
cAMP (PDE7A), 10 nM cAMP (PDE8A), 70nM cGMP (PDE9A), 30 nM cAMP
(PDE10A), and 100 nM cGMP (PDE11A). Inhibitor concentrations that reduce
enzyme activity by 50% (IC50) are presented. The values are means of at least
three independent experiments. Substrate concentrations were 0.1 3 KM for
each enzyme; thus, IC50 values approximate the Ki values.
Mammalian Cell Culture, cAMP Assays, and Immunoblot Analysis
Human NCI-H295R cells were maintained as described (Rainey et al., 1993).
HeLa cells were maintained in DMEM with 10% FBS. Approximately 90%
confluent cells in 12-well dishes were incubated in serum-starved media
for 1 hr, then in 0.5 ml serum-starved media with 20 mM compounds or
0.2% DMSO for 2 hr in the absence or presence of 10 mM forskolin
(Sigma-Aldrich). Media were collected, and cAMP levels were measured as
described (Rainey et al., 1993), using a cAMP ELISA kit (Enzo). cAMP
levels were normalized to protein content measured using a BCA Protein
Assay Kit (Pierce). Immunoblot analysis of protein lysates was per-
formed as described (Sarbassov et al., 2006), using phospho-CREB(9198),
Akt(4685), or CREB(9197) primary antibodies (Cell Signaling Technology)
and goat anti-rabbit IgG-HRP secondary antibody (sc-2030; Santa Cruz
Biotechnology).
Cortisol Assays
H295R cells were treated with compounds as described in the cAMP assays,
for 24 hr. Media were collected, and cortisol content was quantified using
a Cortisol EIA Kit (Oxford Biomedical Research). Cortisol levels were normal-
ized to protein concentrations in cell extracts, as described above.
Semiquantitative RT-PCR
Total cellular RNA was isolated using RNeasy Mini Kits (QIAGEN). cDNA was
synthesized from 2 mg of total RNA using SuperScript II reverse transcriptase
with randomhexamers.PDE11A expressionwas determined by aSYBRGreen
Real-Time PCR assay (ABI) using PDE11A-specific primers (50-TGGAGTG
GATTGATAGCATCTG-30 and 50-TTTGGTGTAGCTCTTCCCAC-30). Expres-
sion levels were normalized to RPLP0 expression (IDT).
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
article online at doi:10.1016/j.chembiol.2011.12.010.
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